# Structure Therapeutics (GPCR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GPCR
## Company Profile
- Ticker: GPCR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 53.91 USD
- Market cap: 2643261250.04 USD
- Last updated: 2026-08-12
## Business Overview
### Structure-Based Metabolic Drug Discovery
Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies.
### Aleniglipron
Aleniglipron is an oral GLP-1 receptor agonist in development for obesity and type 2 diabetes. Phase 2 studies are evaluating long-term weight loss, body composition and metabolic effects ahead of Phase 3 development.
### ACCG-2671
ACCG-2671 is an oral small-molecule amylin-receptor agonist in Phase 1 development. The study includes single- and multiple-ascending-dose evaluation.
### ACCG-3535
ACCG-3535 is a second oral amylin candidate preparing to enter Phase 1 testing, providing Structure with a follow-on molecule in the same therapeutic class.
### Combination-Oriented Franchise
Structure is developing its GLP-1 and amylin candidates as standalone therapies and potential oral combinations, creating multiple development paths within obesity and metabolic disease.
## Why The Stock Is Moving

As of Aug 12, 2026, GPCR closed up 3.41% at $53.91. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of Phase 3 development for aleniglipron in the third quarter of 2026.
- ACCESS open-label-extension data in the third quarter of 2026.
- Initial Phase 1 single-ascending-dose data for ACCG-2671 and initiation of multiple-ascending-dose testing in the third quarter of 2026.
- Body-composition and type 2 diabetes/obesity data for aleniglipron in the fourth quarter of 2026.
- Initiation of a Phase 1 study of ACCG-3535 in the fourth quarter of 2026.

## Recent News
- 2026-08-06 20:05 EST — [Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-second-quarter-2026-financial-results-and-recent--f516f2ee) — Source: Structure Therapeutics
- 2026-06-05 20:05 EST — [Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-pha-725abfa4) — Source: Structure Therapeutics
- 2026-05-26 20:05 EST — [Structure Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Structure Therapeutics
- 2026-05-07 20:06 EST — [Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights) — Source: Structure Therapeutics
- 2026-04-27 20:05 EST — [Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-the-american-diabetes-association-86th-scientific-sessions) — Source: Structure Therapeutics